[144] NewAmsterdam Pharma Company N.V. Warrant SEC Filing

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. (NAMSW) insider Louise Kooij filed a Form 144 reporting a proposed sale of 8,269 ordinary shares (nominal value EUR 0.12). The shares were acquired by RSU vesting on 03/26/2025 and the broker listed is Cooperatieve Rabobank U.A., Utrecht. The filing shows an approximate aggregate market value of $208,296.11 and indicates an intended sale on 08/25/2025 on the Nasdaq Global Market. The issuer's total shares outstanding are reported as 112,628,458. The filer attests there is no undisclosed material adverse information and includes the standard signature/representation language required by the form.

Positive

• Disclosure compliance: Form 144 includes acquisition date, nature (RSU vesting), broker, sale date, and aggregate market value.
• Broker and market specified: Sale is routed through Cooperatieve Rabobank U.A. on the Nasdaq Global Market.

Negative

• No 10b5-1 plan date provided: The filing does not indicate a trading-plan adoption date or instruction date on the form.
• Limited materiality: Filing contains no operational or earnings information; provides only an insider sale notice.

Insights

Securities Compliance Analyst

TL;DR: Routine insider sale disclosure for RSU-vested shares, filed under Rule 144 with broker and sale date specified.

The filing documents a standard Rule 144 notice for shares arising from RSU vesting on 03/26/2025 and a planned sale on 08/25/2025 through Cooperatieve Rabobank U.A. The form includes required elements: class of security, number of shares, aggregate market value, shares outstanding, acquisition date and nature, and broker details. The filer also affirms absence of undisclosed material adverse information as required.

Financial Analyst

TL;DR: Small, routine insider disposition; reduces beneficial holdings but appears procedural rather than company-changing.

The disclosed quantity (8,269 shares) and aggregate market value ($208,296.11) indicate a modest insider sale relative to the reported shares outstanding (112,628,458). Acquisition via RSU vesting is noted, and proceeds from a sale on 08/25/2025 are recorded. The filing contains no operational or financial results and therefore carries limited informational impact on company fundamentals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, nominal value EUR 0.12 per share	Cooperatieve Rabobank U.A. Croeselaan 18 Utrecht P7 3521 CB	8269	208296.11	112628458	08/25/2025	Nasdaq Global Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, nominal value EUR 0.12 per share	03/26/2025	RSU Vesting	NewAmsterdam Pharma Company N.V.			8269	03/26/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Louise Kooij Gooimeer 2-35 Naarden P7 1411 DC	Ordinary shares, nominal value EUR 0.12 per share	08/25/2025	8269	205547.82

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the NAMSW Form 144 report disclose?

The filing reports 8,269 ordinary shares of NewAmsterdam Pharma Company N.V. (nominal value EUR 0.12).

When were the reported shares acquired for NAMSW?

The shares were acquired by RSU vesting on 03/26/2025.

When and where is the proposed sale scheduled?

The proposed sale is scheduled for 08/25/2025 on the Nasdaq Global Market via Cooperatieve Rabobank U.A.

What aggregate value and proceeds are reported for the sale?

The filing shows an approximate aggregate market value of $208,296.11 and gross proceeds reported as $205,547.82 for the sale on 08/25/2025.

Who is the seller named on the Form 144?

The seller is listed as Louise Kooij with an address in Naarden, Netherlands.